Comparative efficacy and safety of pd-1/pd-l1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials

HIGHLIGHTS

• who: Ibrahim Elmakaty from the (UNIVERSITY) have published the research work: Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials, in the Journal: (JOURNAL)
• what: The aim of this Network Meta-Analysis (NMA) is to compare the efficacy and safety of inhibitors of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in treating TNBC.
• how: The authors collected data on the occurrence of common Adverse Events (AEs) in patients from . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.